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Transfusion of Blood Products, Severe Acute
Respiratory Syndrome, and Avian Influenza
Mark R. Looney, MD
Division of Pulmonary and Critical Care Medicine, University of California,
San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USATransfusion of blood products and acute lung
injury and acute respiratory distress syndrome
Clinical spectrum of lung injury secondary
to hemotherapy
The development of lung injury from the
transfusion of blood products occurs on a clinical
spectrum, and therefore the proper recognition of
lung injury must consider these possible scenarios.
Transfusion-related acute lung injury (TRALI), in
its classic and most recognized form, is the
fulminant development of new lung injury in
a patient who has just received or is receiving
a blood-product transfusion. Often, severe re-
spiratory failure develops, and frothy pulmonary
edema fluid is suctioned from the endotracheal
tube. This catastrophic and fulminant form of
TRALI is easily diagnosed by most health care
providers. Like most pathologic processes,
however, TRALI extends on spectrum from mild
to severe, and the milder forms of TRALI can go
unrecognized even by highly trained and experi-
enced health care providers. For example, TRALI
in the stable patient on the general medical ward
who is receiving packed red blood cells (PRBCs)
for anemia and develops a mild decrease in oxygen
saturation may go unrecognized, or the cause of
the oxygen desaturation may be blindly assigned
to volume overload. A recent retrospective study
that tracked the recipients of blood products from
a donor implicated in a case of TRALI exemplifies
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doi:10.1016/j.ccm.2006.06.004this point [1]. This highly motivated donor was
linked to 15 cases of TRALI over a 2-year period,
and many of the cases were associated with mild
symptoms or mild oxygen desaturation. Most of
these cases were not initially recognized as TRALI,
nor were they reported to the blood bank as a po-
tential adverse event. It is essential for the health
care provider to maintain a high degree of vigi-
lance for adverse reactions to blood products and
to investigate thoroughly any oxygen desaturation
temporally related to blood-product transfusion.
Another important category of potential lung
injury related to blood-product transfusion is the
worsening of pre-existing acute lung injury (ALI)
by subsequent hemotherapy. It often is difficult to
make a diagnosis of TRALI in critically ill
patients who have existing ALI/acute respiratory
distress syndrome (ARDS); however, if there is
a sudden worsening of oxygenation and pulmo-
nary compliance in a patient who is receiving or in
the past 6 hours has received a blood-product
transfusion (in the absence of signs of volume
overload), a probable diagnosis of TRALI can be
made. There are a few studies in the medical
literature that support a contribution of blood-
product transfusion to the worsening of pre-
existing ALI/ARDS. Using the largest prospective
study on the incidence of ALI in the pediatric
population, Church and colleagues [2] retrospec-
tively assessed the role of blood-product transfu-
sions on the clinical outcomes of this patient
population. These investigators discovered that
the transfusion of fresh frozen plasma (FFP)
was an independent risk factor for mortality in
these pediatric ALI patients at 30 days. In an
adult prospective investigation of the risk factors,ghts reserved.
chestmed.theclinics.com
592 LOONEYincidence, and outcomes of ALI/ARDS at a single
center, Gong and colleagues [3] reported that
PRBC transfusion was independently associated
with the initial development of ALI/ARDS and
was an independent risk factor for mortality in
ALI/ARDS, with a dose-dependent response.
Potential lessons also can be learned from the
seminal Transfusions Requirements in Critical
Care (TRICC) trial by the Canadian Care Trials
Group [4]. In this randomized, controlled equiva-
lency trial comparing restrictive and liberal trans-
fusion thresholds, the patients transfused with
a hemoglobin trigger of less than 7 g/dL had at
least as good outcomes as the patients in the
liberal transfusion arm. In an analysis of the
ICU complications that developed in the two
groups of patients, 32 patients (7.7%) in the re-
strictive transfusion group versus 48 patients
(11.4%) in the liberal transfusion group developed
ARDS during their ICU stay (P ¼ .06). Unfortu-
nately, it was not determined what proportion of
these patients who had ARDS developed overt
TRALI; however, it is provocative to consider
that a proportion of ARDS may be preventable
by adhering to lower transfusion thresholds.
This potential benefit could result from the reduc-
tion of ALI/ARDS directly caused by the transfu-
sion of blood products and ALI/ARDS resulting
from the combination of blood transfusions and
other causes (the two-hit model). In the TRICC
trial, decreased infectious complications (eg,
pneumonia, sepsis) did not seem to be a benefit
of the restrictive transfusion group, and thus the
decreased incidence of ALI/ARDS probably can-
not be attributed to decreased transfusion-related
immunomodulation. One other notable point to
consider regarding the TRICC trial was the
statistically significant decrease in pulmonary
edema in the restrictive transfusion group. Pulmo-
nary edema was listed as a cardiac complication,
although it is unclear how rigorously noncardio-
genic pulmonary edema was excluded. This
decrease in pulmonary edema could potentially
comprise both transfusion-associated circulatory
overload and TRALI.
Definition of transfusion-related acute lung injury
The term ‘‘transfusion-related acute lung in-
jury’’ was first coined in 1983 by Popovsky and
Moore [5] and has been variably defined in the
ensuing years. Recently, the field has been aided
significantly by a consensus definition developed
by a panel investigators convened by the Nationalheart, Lung, and Blood Institute (NHLBI) [6].
Simply put, TRALI remains a clinical diagnosis,
similar to the clinical definition used for ALI/
ARDS [7]. In fact, if a patient meets clinical criteria
for ALI/ARDS and has received a blood-product
transfusion during the previous 6 hours (in the
absence of another credible risk factor for
ARDS), a clinical diagnosis of TRALI can be
made. The blood bank and laboratory work-up
of TRALI is an important component for the
possible prevention of future TRALI from
implicated blood donors, but it is not required
to make a diagnosis of TRALI.
The use of the 6-hour window to implicate
a blood-product transfusion in TRALI is not an
arbitrary designation. The multitude of case re-
ports in the medical literature confirms a close
temporal association with the transfusion of
blood products. In fact, it is common for TRALI
to develop during the first 30 to 60 minutes of
a transfusion [8]. Experimental evidence from an-
imal models supports this temporal association. In
at least four different animal models of TRALI
using anti-neutrophil antibodies, anti–major his-
tocompatibility class (MHC) I antibodies, and
the plasma and lipid fractions from day 42 PRBCs
and day 5 platelets, lung injury develops within
6 hours of challenge with these experimental
agents [9]. In fact, in the MHC I antibody model,
lung injury develops within 2 hours and often
within 15 to 30 minutes [10]. The speed with which
lung injury develops in a given patient is probably
a complex interplay of host susceptibility and dose
or titer of the injurious blood product.
The clinical diagnosis of TRALI is potentially
complicated by the existence of other major risk
factors for ALI/ARDS, clinical risk factors that
often are present in critically ill patients receiving
hemotherapy. The consensus definition of TRALI
addresses this point by assigning a definite di-
agnosis of TRALI when no other ALI/ARDS
risk factors are present and a probable diagnosis
of TRALI when these other major risk factors
are present [6]. The clinical course of these
probable TRALI patients can be followed over
time, and the credibility of the relationship of
the risk factors to ALI/ARDS can be assessed.
If hemotherapy remains the most credible risk fac-
tor for ALI/ARDS, a diagnosis of TRALI can be
made.
The issue of massive transfusions as a risk
factor for ALI/ARDS is a potential source of
confusion in assigning the diagnosis of TRALI.
Massive transfusion is defined as the replacement
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blood volume over 12 to 24 hours [11]. Massive
transfusion has been implicated as a major risk
factor for ALI/ARDS in multiple studies and is
probably the fourth most common cause of
ALI/ARDS, accounting for approximately 20%
of cases. Even with the experimental models of
massive blood transfusion, it is not entirely clear
how lung injury is produced by this insult.
Because many of these patients, if not the major-
ity, are involved in trauma, considerations include
ischemia-reperfusion lung injury from shock and
potentially a component of direct thoracic
trauma. Older investigations using animal models
of ‘‘shock lung’’ disproved the microaggregate or
particulate theory of lung injury from transfusions
but focused attention on the plasma fraction of
blood products [9]. Is it possible that the develop-
ment of ALI/ARDS from massive blood transfu-
sion is a function of the cumulative risk of TRALI
from individual blood products? This supposition
may explain many of the cases; receiving multiple
blood products places the patient at higher risk of
receiving an incompatible product containing
either a matched antibody or priming or activat-
ing bioactive lipids. If one considers the two-hit
model of TRALI, then the underlying medical
condition of the critically ill patient who is requir-
ing multiple transfusions also places the patient at
risk for TRALI. In summary, the certainty by
which a diagnosis of TRALI can be made in a pa-
tient who has other risk factors for ALI or pre-
existing ALI is a complicated issue that may be
aided by following the clinical course of the pa-
tient and also by focused laboratory investigation
of implicated blood products.
Incidence and clinical outcomes
The most consistent incidence of TRALI
reported in the medical literature is 1 in 5000
blood products transfused. [5]. This figure is prob-
ably a significant underestimation given the
evidence for the under-recognition and under-
reporting of TRALI [1]. The new consensus
definition and the recent proliferation of case re-
ports and clinical reviews of TRALI should aid
in the greater recognition and reporting of this
condition in the future. In addition, the NHLBI
has recently funded a Specialized Centers of Clin-
ically Oriented Research (SCCOR) grant to the
University of California, San Francisco and the
Mayo Clinic, Rochester to conduct a prospective
observational cohort study on the incidence andoutcomes of TRALI at these two medical centers.
This study promises to yield the largest cohort of
TRALI patients in the medical literature and
should provide a reliable estimate of the incidence
of TRALI.
Medical providers are required to report fatal-
ities related to TRALI to the Food and Drug
Administration (FDA). During the past few years
the FDA has received between 8 and 21 reports
per year of fatal TRALI, and TRALI has now
emerged as the primary cause of transfusion-
associated mortality, surpassing infectious com-
plications and ABO mismatch [12,13]. The United
Kingdom’s Serious Hazards of Transfusion An-
nual Report for 2004 evaluated 23 cases that
had been reported as TRALI events and con-
cluded that 13 cases were either highly likely or
probable TRALI, and 4 of these cases were possi-
ble TRALI [14].
The clinical outcomes of patients who have
TRALI differ considerably from the outcomes of
patients who have all causes of ALI/ARDS. One
of the largest case series in the TRALI literature
reported the clinical outcomes of 36 patients at the
Mayo Clinic in the mid-1980s, predating the use
of low tidal volume ventilation in the management
of patients who have ALI/ARDS [15]. In this in-
vestigation, three quarters of the patients required
mechanical ventilation, and the vast majority of
the patients had rapid clearance (!96 hours) of
the pulmonary edema. Two of the 36 patients
died, yielding a mortality of 6%. The rapid clear-
ance of the pulmonary edema and mortality differ
considerably from all-cause ALI/ARDS, which
has an estimated mortality of 30% to 40% [16].
Implicated blood products in transfusion-related
acute lung injury
All plasma-containing blood products have
been implicated in TRALI. This list includes
whole blood, PRBCs, FFP, whole blood platelets,
and apheresis platelets, with less frequent associ-
ations with intravenous immunoglobulin and
cryoprecipitate. Controversy exists concerning
which blood product is most commonly impli-
cated in TRALI, but the two blood products with
the largest plasma fraction, FFP and platelets, are
probably the top offenders. In the reports of
TRALI fatalities reported to the FDA, FFP was
the most commonly implicated product, followed
by red blood cells, platelets, and cryoprecipitate
[13]. The association of platelets with TRALI
is supported by a single-center investigation
594 LOONEYreporting that whole blood platelets caused
TRALI in 72 of 90 cases [17].
Pathogenesis of transfusion-related
acute lung injury
Classically, the pathogenesis of TRALI has
been explained by the passive transfusion of
a plasma-containing blood product with a HLA
class I/II or neutrophil antibody that recognizes
specific HLA or neutrophil antigens in the
recipient. Numerous case reports and case series
have documented the presence of these antibodies
and the matching antigens in the recipient, and in
animal models MHC I and anti-neutrophil anti-
bodies have produced acute lung injury
[8,10,18,19]. In rarer circumstances, roles can be re-
versed, and recipient antibodies can react with anti-
gens on donor leukocytes. In the FDA’s report on
fatalities secondary to TRALI, anti-HLA I anti-
bodies were the most frequently implicated anti-
body, followed by anti-granulocyte and anti-HLA
II antibodies [13]. In an anti–MHC I mouse model
that reproduces many features of clinical TRALI,
lung injury was produced secondary to the recogni-
tion of endothelial-bound MHC I antibody by
circulating neutrophils and their Fc gamma
receptors [10]. In another experimental model of
TRALI, evidence was presented that a mouse
monoclonal anti-neutrophil antibody directly acti-
vated human neutrophils, leading to lung injury
[19]. Common to all antibody models, however, is
the central role of the neutrophil in producing dis-
ease, either from direct antibody activation or indi-
rectly through Fc gamma receptor activation.
Other investigators have shown that monocytes
may be important in TRALI pathogenesis [20].
Although the antibody theory of TRALI is
supported by both clinical and experimental
evidence, solid clinical data and animal models
also implicate biologically active lipids that
accumulate in older cellular blood products
[21–23]. These biologically active lipids, thought
to be breakdown products of cellular mem-
branes from stored blood products, can prime
and activate neutrophils in vitro. Cellular blood
products (PRBCs, platelets) have been shown to
accumulate these lipids over time, and the
plasma and lipid fractions from these older
blood products have been used to produce pul-
monary edema in isolated, perfused rat lung
models. Older blood products have been impli-
cated in TRALI cases [17] but recently, redblood cell storage time was not associated with
the development of new ALI/ARDS [24].
A phenomenon that has not been adequately
explained is the inconsistent development of lung
injury even when a recipient is transfused with
a matched HLA or neutrophil antibody. For
example, a retrospective study of TRALI involv-
ing an antibody to a neutrophil antigen expected
to be present in more than 90% of recipients
produced TRALI in only a minority of patients
transfused with this antibody [1]. This lack of
a consistent relationship between antibody-
antigen matches and TRALI has been explained
by host susceptibility and specifically by the two-
hit model of TRALI. This hypothesis states that
the recipient must have an underlying medical
condition that contributes to immune priming
and that with the transfusion of HLA or neutro-
phil antibody or biologically active lipids (or
both), TRALI is produced. Evidence supporting
this hypothesis includes the frequent occurrence
of TRALI in the ICU or operating room and
epidemiologic associations with cardiopulmonary
bypass and hematologic malignancies [17]. In ad-
dition, the biologically active lipid model involves
a necessary systemic endotoxin-priming step to
produce ALI [22,23]. Host susceptibility factors
such as genetic polymorphisms also may be
contributing factors.
Clinical manifestations, diagnosis, and management
of transfusion-related acute lung injury
Patients who develop TRALI often develop
dyspnea, tachypnea, and hypoxia. Both hypoten-
sion and hypertension have been reported in
patients who have TRALI, as has hyper- and
hypothermia. In mechanically ventilated patients
or at the time of endotracheal intubation, frothy
pulmonary edema fluid is sometimes elaborated in
fulminant TRALI cases. The same criteria used by
clinicians and researchers to diagnose other causes
of ALI/ARDS are used to make a diagnosis of
TRALI [7]. Chest imaging reveals bilateral
pulmonary opacities in a pattern consistent with
noncardiogenic pulmonary edema (Fig. 1). Ad-
junctive tests that aid in a TRALI diagnosis
include echocardiography, serial white blood cell
counts, and the protein analysis of undiluted
pulmonary edema fluid [8]. Echocardiography
can aid in the work-up by helping exclude volume
overload and cardiogenic dysfunction. Often, pa-
tients who have fulminant TRALI have evidence
of low cardiac filling pressures. Measurement of
595NEWLY RECOGNIZED CAUSES OF ALIFig. 1. (A) Anterior-posterior chest radiograph in a 43-year-old woman recovering from knee surgery who developed
respiratory distress and hypoxia during a PRBC transfusion. Bilateral pulmonary opacities are present. (B) Chest CT
in the same patient revealing bilateral ground-glass opacities and interstitial septal thickening. CT was done 24 hours
after the chest radiograph in Fig. 1A.brain natriuretic peptide may also be an
adjunctive test that can be helpful. There are
several case reports of leukopenia and neutrope-
nia temporally associated with the onset of pul-
monary edema in TRALI [25–28]. This
laboratory finding often is dynamic, with leuko-
cyte counts recovering a few hours after the initi-
ation of TRALI. There is even one case report of
leukopenia heralding the onset of TRALI [29].
The mouse MHC I antibody model of TRALI
also has documented this phenomenon, which
speaks to the association of leukopenia with
disease pathogenesis [10]. Other causes of ALI/
ARDS (eg, pneumonia, sepsis) also might produce
leukopenia, so this finding is not specific to
TRALI. Thrombocytopenia and decreased com-
plement have been reported also, but much less
frequently. Finally, if present, the measurement
of the protein concentration of undiluted
pulmonary edema fluid and a matched plasma
sample can be helpful in documenting a permeabil-
ity pulmonary edema and thus helping exclude
transfusion-associated circulatory overload or
cardiogenic pulmonary edema [30].
There is no unique or specific treatment for
TRALI, but the proper recognition of this syn-
drome leads to provision of the same supportive
care given to any patient who has ALI/ARDS.
Additionally, correctly identifying TRALI allows
one to avoid potentially injurious interventions,
such as diuretics, in these patients, who often are
volume depleted. Paradoxically, these patients,
who sometimes have severe pulmonary edema,
may require intravenous fluids to support blood
pressure. Colloid and vasopressors may berequired in some instances. Corticosteroids have
no role in the treatment of TRALI patients. It is
important to consider that most patients who
have TRALI improve fairly rapidly, and overall
mortality is low; thus, with patience and the
avoidance of any unnecessary blood-product
transfusions, most patients will do well.
Prevention of transfusion-related acute lung injury
TRALI is best prevented by avoiding unnec-
essary blood-product transfusions using evidence-
based transfusion triggers. Use of erythropoietin
[31] and recombinant factor VII may help reduce
transfusion requirements in selected populations.
Most experts agree that if a blood donor is impli-
cated in a TRALI case, that donor and the do-
nor’s existing blood products should be removed
permanently from the donor pool. Given the inci-
dence of HLA sensitization in multiparous fe-
males [32] and the association of TRALI with
FFP transfusion, the United Kingdom has ex-
cluded all women from donating FFP, directing
their donations instead to plasma-poor blood
products [14]. In addition, platelet pools are sus-
pended in male plasma as much as possible. There
has not been ample time to determine the benefit
of this regulatory action on the incidence of
TRALI; however, the number of highly likely or
probable TRALI cases decreased from 22 in
2003 to 13 cases in 2004. (The FFP policy was im-
plemented in October 2003.) Given time delays in
the work-up of TRALI cases and the long shelf-
life of stored FFP, the true impact of the male-
only FFP policy change will not be known until
596 LOONEYthe next reporting years. Leukoreduction of
PRBCs is now an almost universal blood bank
procedure, but it is unlikely that it will signifi-
cantly reduce the incidence of TRALI, because re-
cipient antibody recognition of antigens on donor
leukocytes is a rare mechanism in TRALI.
Severe acute respiratory syndrome
Clinical importance and epidemiology of severe
acute respiratory syndrome
The severe acute respiratory syndrome (SARS)
burst on the international scene in 2002 and 2003
causing much concern because of its rapid, global
dissemination and fears of a pandemic. From late
2002 to mid-2003, more than 8000 people de-
veloped probable SARS in many different coun-
tries across five continents, with the predominance
of cases in China, Hong Kong, Viet Nam,
Taiwan, Singapore, and Canada. Approximately
one in four patients who had SARS become
critically ill, with ALI occurring in 80% of these
patients (16% of all patients). In fact, ALI is the
most common organ-system dysfunction in SARS
patients. Of the patients who become critically ill
with SARS, approximately 50% die, with mortal-
ity rates increased in the elderly [33].
Much has been learned about the epidemiol-
ogy of SARS since its emergence in the Guang-
dong Province of China. Remarkably, through
collaborations with multiple laboratories in dif-
ferent countries, a novel coronavirus was identi-
fied as the causative agent of SARS just 4 to
5 months after the initial reports of the SARS
outbreak [34,35]. A similar coronavirus was also
isolated from wild animals (eg, Himalayan palm
civets, raccoon dogs) sold in the ‘‘wet’’ markets
in Guangdong Province, supporting a zoonotic
origin of this novel virus [36]. The incubation pe-
riod for SARS seems to range between 2 and 10
days, although longer incubation times have
been documented. Unlike influenza, in which
transmissibility peaks soon after the onset of clin-
ical symptoms, SARS is transmitted most effi-
ciently after 10 days of illness. The primary
route of transmission is contact (direct or indirect)
with respiratory droplets or fomites. Fecal–oral
spread also may play a role, given the presence
of SARS coronavirus in stool specimens and the
presence of watery diarrhea in many affected pa-
tients. The spread of SARS seems to involve so-
called ‘‘super-spreaders’’ who disproportionatelyinfect many persons, and it also prominently in-
volves transmission in the health-care setting [37].
Pathogenesis of severe acute respiratory syndrome
A Clinical SARS Working Group, comprised
of experts from Canada and the United States,
determined that patients admitted to ICUs with
respiratory failure secondary to SARS met the
established clinical definition of ALI/ARDS [33].
Lung pathology obtained from SARS nonsurvi-
vors reveals a pattern of disease that is indistin-
guishable from other causes of ALI/ARDS,
namely diffuse alveolar damage [38].
Much has been learned about the potential
cellular and molecular mechanisms of lung injury
secondary to SARS coronavirus infection. For
example, the tropism of the SARS coronavirus for
the lung and the gastrointestinal tract can be
explained by the epithelial distribution of its
cellular receptor, ACE-2, which is found on the
surface of alveolar type I and II epithelial cells and
also on small bowel enterocytes [39,40]. Therefore,
the severe pulmonary damage observed in SARS
can be explained by viral–alveolar epithelial cell
interaction.
Diagnosis, management, and prevention
of severe acute respiratory syndrome
SARS presents clinically with a nonspecific
viral syndrome of fever, myalgia, chills, fatigue,
and cough; upper respiratory symptoms (eg,
rhinorrhea, sore throat) are often absent. Watery
diarrhea can be present in some patients. Severely
affected patients develop shortness of breath,
tachypnea, and tachycardia. Routine laboratory
investigation often reveals lymphopenia, throm-
bocytopenia, and elevated transaminases. Chest
imaging is nonspecific with high-resolution CT
being abnormal in nearly all patients showing
ground-glass attenuation and focal consolidation
with some cases of pneumomediastinum [37].
The diagnosis of SARS relies on consideration
of key epidemiologic data in a patient who has
a viral syndrome or idiopathic respiratory failure.
Because the clinical syndrome, routine laboratory
testing, and chest imaging are nonspecific,
diagnosis relies on detection of the SARS coro-
navirus in clinical specimens. Real-time polymer-
ase chain reaction (PCR) is used to test samples
from multiple potential sites, including the upper
and lower respiratory tracts, stool, urine, and
plasma. The virus concentrates in the lower
respiratory tract and is present in low quantities
597NEWLY RECOGNIZED CAUSES OF ALIearly in the disease course; thus negative results
early in the clinical course, especially from upper
respiratory specimens, should be interpreted with
caution. The standard diagnostic test for SARS is
seroconversion, but this testing is rarely helpful
prospectively.
The evidence-based management of SARS has
been reviewed by the NHLBI/Centers for Disease
Control and Prevention/National Institute of
Allergy and Infections Diseases Clinical SARS
Working Group [33]. Generically, because SARS
produces a clinical syndrome consistent with other
causes of ALI/ARDS, respiratory failure should
be managed in a similar fashion, with a pressure-
limited, low tidal volume strategy. The roles of
antiviral agents (eg, ribavirin and interferon-a)
and corticosteroids are controversial and suffer
from the lack of quality data. Anecdotal and small
case series have supported the role of corticoste-
roids for severe cases [41], and thus, in the absence
of placebo-controlled trials, steroid therapy should
be considered, especially in patients who have
clinical deterioration.
Several factors contributed to the halt of SARS
transmission and its current disappearance from
the clinical landscape. The involvement by the
World Health Organization in issuing a global
health alert, the quarantine of infected and
exposed individuals, and, importantly, the ban
on the sale of wildlife in the wet markets of
Guangdong, China all helped to stop the spread
of this potential pandemic. Phase I trials are now
in progress on vaccine strategies that could prove
to be important should SARS re-emerge on the
global scene [42].
Avian influenza (H5N1)
Clinical importance and epidemiology
of H5N1 infection
Influenza pandemics have been marked by the
emergence of epizootic strains of influenza for
which there is no immunologic memory in hu-
mans. The Spanish influenza (H1N1) pandemic of
1918 killed an estimated 40 to 50 million people
worldwide. Subsequent pandemics in 1957 (H2N2)
and 1968 (H3N2) also killed many thousands.
Attention and trepidation are now focused on the
H5N1 epizootic strain and its potential to cause
worldwide disease and mortality. The H5N1 virus
first emerged in 1959 in chickens in Scotland and
now is causing a pandemic among chickens in
Southeast Asia [43]. According to World HealthOrganization statistics accessed on June 5, 2006,
224 humans have been infected with H5N1 virus
in 10 different countries, and 127 have died, yield-
ing a mortality of 57%, many of which are children
and young adults [44]. Almost all the persons in-
fected with H5N1 have been linked epidemiologi-
cally with exposure to sick birds or, in a very
small number of cases, to exposure to another hu-
man who had H5N1 infection. It is unknown just
how widespread and lethal a pandemic of H5N1
infection would be, but the Congressional Budget
Office estimates that 200 million people could be
infected in the United States alone.
H5N1 disease pathogenesis
The H5N1 influenza A subtype contains a new
H5 hemagglutinin to which humans have little
immunity. The hemagglutinin molecules attach to
epithelial cells and macrophages in the lungs by
interaction with cell-surface sialic acid residues.
A true influenza pandemic can develop only if the
avian H5N1 virus can spread efficiently from
human to human, a scenario that has occurred
only rarely thus far. Recent reports might help
explain why the avian H5N1 virus currently is
inefficient in human-to-human infection. It seems
that established human influenza viruses (eg,
H1N1) and avian flu viruses target different
regions of the human respiratory tract. Human flu
viruses preferentially recognize sialic acid residues
in the proximal respiratory tract (trachea and
bronchi), whereas H5N1 infects alveolar type II
cells, macrophages, and the nonciliated cuboidal
epithelium of the terminal bronchi [45,46]. This
differential tropism may help explain the clinical
presentation of ALI/ARDS in humans infected
with H5N1, and perhaps more importantly, it
may help explain why H5N1 is not transmitted ef-
ficiently among humans: human influenza is trans-
mitted easily from its proximal location in the
respiratory tract, whereas H5N1 is a more deeply
seated infection. There is even some concern from
animal models of H5N1 infection that viremia
can lead to fecal shedding of the virus and the
potential for fecal–oral transmission.
Diagnosis, management, and prevention
of H5N1 infection
Children and young adults seem to be dispro-
portionately affected by H5N1 infections, with
median ages of affected individuals ranging from
9.5 to 22 years [47]. H5N1 infection has typical
influenza-like symptoms but prominently involves
598 LOONEYthe lower respiratory tract and often is accompa-
nied by a watery diarrhea. Like SARS, lymphope-
nia, thrombocytopenia, and increased
transaminase levels are often present. The most
common radiographic findings are multifocal
consolidations, and progression to respiratory
failure occurs in the majority of hospitalized indi-
viduals within 48 hours of admission. Diagnosis
relies on consideration of the appropriate epide-
miologic context in conjunction with reverse
transcriptase PCR of respiratory samples, with
pharyngeal samples having a higher yield than
nasal specimens.
From what is currently known, the treatment
of H5N1 infection does not deviate substantially
from the treatment of severe human influenza
infections. Supportive care for patients who have
H5N1-associated ALI/ARDS should include
a pressure-limited, low tidal volume ventilatory
strategy. For antiviral treatment, some data in-
dicate that many of the H5N1 strains isolated
from humans are resistant to the adamantanes
[48], to which the current circulating human
influenza strains also have recently become highly
resistant. The H5N1 strains isolated from humans
have proven susceptible to the neuraminidase in-
hibitors oseltamivir (Tamiflu) and zanamivir (Re-
lenza), although there have been case reports of
isolates resistant to oseltamivir [49]. Prophylaxis
of health care workers and postexposure prophy-
laxis would be essential elements of the response
to a pandemic, provided that adequate supplies
of neuraminidase inhibitors are available. The po-
tential role of corticosteroids in the treatment of
influenza-associated ALI/ARDS is not known.
Like the primary focus in the annual influenza
season, prevention of H5N1 infection is justly
receiving a great deal of attention. Researchers
from throughout the world are racing to develop
a vaccine that is highly effective, has low side
effects, and can be mass produced in a short
period of time. Multiple strategies are being used
to produce an immunogenic vaccine. A recent
report used two doses of an inactivated subvirion
H5 vaccine administered intramuscularly to
humans and showed that, at the highest dose of
the vaccine administered, approximately half of
the patients developed neutralizing antibody titers
[50]. The 50% effectiveness of this vaccine con-
trasts with the 70% to 90% effectiveness of
human influenza vaccines in current use. It has
been proposed that the use of an adjuvant may in-
crease H5 vaccine effectiveness, because new
hemagglutinin proteins in humans may be poorlyimmunogenic. Other groups are testing live atten-
uated influenza vaccines and also adenovirus-
based immunization strategies, which can elicit
a strong T-cell immunity response.
Summary
TRALI, SARS, and H5N1 influenza are re-
cently described causes of ALI/ARDS from which
much has been learned, but many questions
remain unanswered. The biggest impact on de-
creasing the incidence of TRALI will be from
adherence to evidence-based transfusion guide-
lines and potentially from regulatory action that
limits exposure to blood products or donors that
have been consistently implicated in TRALI. The
outcomes of recent initiatives by the United
Kingdom limiting exposure to female plasma
will be followed closely to determine if similar
action should be taken in the United States. With
the threat of SARS temporarily under control,
attention is intensely focused on the pandemic
threat of H5N1 influenza, which has the potential
to overwhelm existing critical care resources for
the treatment of respiratory failure. Undoubtedly,
new infectious and noninfectious causes of ALI/
ARDS will emerge in the future, mandating
vigilance by health care providers, providing
a challenge to public health officials and clinical
and basic science investigators, and requiring
transparent communication among the members
of today’s global society.
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